Literature DB >> 25196047

Candidate drug targets for prevention or modification of epilepsy.

Nicholas H Varvel1, Jianxiong Jiang, Raymond Dingledine.   

Abstract

Epilepsy is a prevalent neurological disorder afflicting nearly 50 million people worldwide. The disorder is characterized clinically by recurrent spontaneous seizures attributed to abnormal synchrony of brain neurons. Despite advances in the treatment of epilepsy, nearly one-third of patients are resistant to current therapies, and the underlying mechanisms whereby a healthy brain becomes epileptic remain unresolved. Therefore, researchers have a major impetus to identify and exploit new drug targets. Here we distinguish between epileptic effectors, or proteins that set the seizure threshold, and epileptogenic mediators, which control the expression or functional state of the effector proteins. Under this framework, we then discuss attempts to regulate the mediators to control epilepsy. Further insights into the complex processes that render the brain susceptible to seizures and the identification of novel mediators of these processes will lead the way to the development of drugs to modify disease outcome and, potentially, to prevent epileptogenesis.

Entities:  

Keywords:  anticonvulsant; cytokines; disease modification; epileptogenesis; neuroinflammation; neuroprotection

Mesh:

Substances:

Year:  2014        PMID: 25196047      PMCID: PMC4427904          DOI: 10.1146/annurev-pharmtox-010814-124607

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  139 in total

Review 1.  Role of transforming growth factor beta in human disease.

Authors:  G C Blobe; W P Schiemann; H F Lodish
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

2.  In contrast to kindled seizures, the frequency of spontaneous epilepsy in the limbic status model correlates with greater aberrant fascia dentata excitatory and inhibitory axon sprouting, and increased staining for N-methyl-D-aspartate, AMPA and GABA(A) receptors.

Authors:  G W Mathern; E H Bertram; T L Babb; J K Pretorius; P A Kuhlman; S Spradlin; D Mendoza
Journal:  Neuroscience       Date:  1997-04       Impact factor: 3.590

3.  Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke.

Authors:  G T Manley; M Fujimura; T Ma; N Noshita; F Filiz; A W Bollen; P Chan; A S Verkman
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

4.  Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials.

Authors:  N R Temkin
Journal:  Epilepsia       Date:  2001-04       Impact factor: 5.864

5.  Kainic acid-induced mossy fiber sprouting and synapse formation in the dentate gyrus of rats.

Authors:  H J Wenzel; C S Woolley; C A Robbins; P A Schwartzkroin
Journal:  Hippocampus       Date:  2000       Impact factor: 3.899

6.  Kainate-induced seizures alter protein composition and N-methyl-D-aspartate receptor function of rat forebrain postsynaptic densities.

Authors:  U Wyneken; K H Smalla; J J Marengo; D Soto; A de la Cerda; W Tischmeyer; R Grimm; T M Boeckers; G Wolf; F Orrego; E D Gundelfinger
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

Review 7.  Glutamate uptake.

Authors:  N C Danbolt
Journal:  Prog Neurobiol       Date:  2001-09       Impact factor: 11.685

8.  Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus.

Authors:  M G De Simoni; C Perego; T Ravizza; D Moneta; M Conti; F Marchesi; A De Luigi; S Garattini; A Vezzani
Journal:  Eur J Neurosci       Date:  2000-07       Impact factor: 3.386

Review 9.  The role of cytokines and growth factors in seizures and their sequelae.

Authors:  J L Jankowsky; P H Patterson
Journal:  Prog Neurobiol       Date:  2001-02       Impact factor: 11.685

10.  Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice.

Authors:  A Vezzani; D Moneta; M Conti; C Richichi; T Ravizza; A De Luigi; M G De Simoni; G Sperk; S Andell-Jonsson; J Lundkvist; K Iverfeldt; T Bartfai
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

View more
  33 in total

Review 1.  Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus.

Authors:  Yifeng Du; Timothy Kemper; Jiange Qiu; Jianxiong Jiang
Journal:  Expert Rev Neurother       Date:  2016-01-13       Impact factor: 4.618

2.  Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury.

Authors:  Jianxiong Jiang; Ying Yu; Erika Reime Kinjo; Yifeng Du; Hoang Phuong Nguyen; Ray Dingledine
Journal:  Neuropharmacology       Date:  2019-02-11       Impact factor: 5.250

3.  2014 Epilepsy Benchmarks: Progress and Opportunities.

Authors:  Cara Long; Brandy Fureman; Ray Dingledine
Journal:  Epilepsy Curr       Date:  2016 May-Jun       Impact factor: 7.500

4.  2014 Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression.

Authors:  Aristea S Galanopoulou; Michael Wong; Devin Binder; Adam L Hartman; Elizabeth M Powell; Avtar Roopra; Richard Staba; Annamaria Vezzani; Brandy Fureman; Ray Dingledine
Journal:  Epilepsy Curr       Date:  2016 May-Jun       Impact factor: 7.500

5.  d-Leucine: Evaluation in an epilepsy model.

Authors:  Kylie Holden; Adam L Hartman
Journal:  Epilepsy Behav       Date:  2017-11-07       Impact factor: 2.937

6.  Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy.

Authors:  Alberto Pauletti; Gaetano Terrone; Tawfeeq Shekh-Ahmad; Alessia Salamone; Teresa Ravizza; Massimo Rizzi; Anna Pastore; Rosaria Pascente; Li-Ping Liang; Bianca R Villa; Silvia Balosso; Andrey Y Abramov; Erwin A van Vliet; Ennio Del Giudice; Eleonora Aronica; Manisha Patel; Matthew C Walker; Annamaria Vezzani
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

Review 7.  Glial source of nitric oxide in epileptogenesis: A target for disease modification in epilepsy.

Authors:  Shaunik Sharma; Sreekanth Puttachary; Thimmasettappa Thippeswamy
Journal:  J Neurosci Res       Date:  2017-12-12       Impact factor: 4.164

8.  Novel Targets for Developing Antiseizure and, Potentially, Antiepileptogenic Drugs.

Authors:  Dipan C Patel; Karen S Wilcox; Cameron S Metcalf
Journal:  Epilepsy Curr       Date:  2017 Sep-Oct       Impact factor: 7.500

9.  Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus.

Authors:  Nicholas H Varvel; Jonas J Neher; Andrea Bosch; Wenyi Wang; Richard M Ransohoff; Richard J Miller; Raymond Dingledine
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

Review 10.  Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside.

Authors:  Avijit Dey; Xu Kang; Jiange Qiu; Yifeng Du; Jianxiong Jiang
Journal:  Trends Pharmacol Sci       Date:  2016-04-06       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.